4168.Two
4168.TWO operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
Business. 4168.TWO operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4168.TWO operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
The company's capital structure is characterized by a debt-to-equity ratio of 0.48, indicating a relatively conservative leverage position. However, the company's liquidity is assessed as medium, with a current ratio of 8.0, suggesting strong short-term liquidity. Despite this, the company has negative net cash after subtracting total debt, which is a key liquidity flag.
Profitability metrics show a return on equity of -0.2395 and a return on assets of -0.1513, both of which are negative and significantly below the industry median for a biotechnology firm. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit.
The company's revenue is concentrated in a single segment, as no additional segments are disclosed. Geographically, the company's exposure is not specified in the available data, but the lack of segmental breakdown suggests a potential concentration risk in terms of product or market reliance.
Looking at the growth trajectory, the company is expected to see a significant decline in earnings per share (EPS) from 2.16 TWD to -1.86 TWD, according to analyst estimates. This indicates a challenging outlook for the company's profitability in the near term. The mean revenue estimate of 51,000,000 TWD suggests a slight increase in revenue, but the mean EBIT estimate of -212,000,000 TWD indicates continued operational losses.
The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure for share issuance. The company's capital expenditures are relatively modest, with a free cash flow of -207,623,000 TWD, indicating that the company is not generating sufficient cash to fund its operations and investments.
Recent events and filings do not provide specific details on the company's strategic moves or operational changes. The company's financial performance, as reflected in the operating cash flow of -166,287,000 TWD and free cash flow of -207,623,000 TWD, suggests ongoing financial stress. The company's capital structure and liquidity position will be critical to monitor in the coming periods.
- The company has a negative return on equity and return on assets, indicating poor profitability.
- The company's liquidity is medium, with a high current ratio but negative net cash after debt.
- The company is expected to see a significant decline in EPS, suggesting a challenging earnings outlook.
- The company's capital expenditures are modest, but the free cash flow is negative, indicating financial stress.
- The company's risk assessment indicates a medium liquidity risk and low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,86 |
| Revenue | —no estimate | —no estimate | 51,0M TWD |
| Operating income | —no estimate | —no estimate | -212,0M TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4168.TWO Market data — financials · 2026-05-26
- GlycoNex Inc Market data — analyst estimates · 2026-05-26